Daniela Gompelmann

Prof. Dr. Daniela Gompelmann


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2012 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
FHFelix J.F. Herth
Felix J.F. Herth
RERalf Eberhardt
Ralf Eberhardt
DGDaniela Gompelmann
Daniela Gompelmann
JFJoachim H. Ficker
Joachim H. Ficker
MWManfred Wagner
Manfred Wagner
DSDirk-Jan Slebos
Dirk-Jan Slebos
One-way endobronchial valves (EBVs) have been shown to relieve symptoms of emphysema, particularly in patients without collateral ventilation (CV) between the target and adjacent lobes. In this study, we investigated the ability of the bronchoscopic Chartis™ Pulmonary Assessment System to predict treatment response by determining the presence of CV.80 EBV patients underwent a pre-treatment Chartis assessment. Before and 30 days after implantation, high-resolution computed tomography scans were taken to determine target lobe volume reduction (TLVR). A pre- to post-treatment reduction of ≥350 mL was defined as significant. In addition, clinical outcomes (forced expiratory volume in 1 s (FEV1), 6-min walk test and St George’s Respiratory Questionnaire) were compared over the same time period.Of the 51 patients classified as having an absence of CV according to their Chartis reading, 36 showed a TLVR ≥350 mL. 29 patients were classified as having CV, and of these 24 did not meet this TLVR cut-off. Chartis showed an accuracy level of 75% in predicting whether or not the TLVR cut-off would be reached. Those predicted to respond showed significantly greater TLVR (p<0.0001) and FEV1improvement (p=0.0013) than those predicted not to respond.Chartis is a safe and effective method of predicting response to EBV treatment.

1 March 2016 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
FHFelix J F Herth
Felix J F Herth
AVArschang Valipour
Arschang Valipour
PSPallav L Shah
Pallav L Shah
RERalf Eberhardt
Ralf Eberhardt
CGChristian Grah
Christian Grah
DGDaniela Gompelmann
Daniela Gompelmann

1 September 2009 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
FHFelix Herth
Felix Herth
RERalf Eberhardt
Ralf Eberhardt
DADevanand Anantham
Devanand Anantham
DGDaniela Gompelmann
Daniela Gompelmann
MZMohamed Wafaa Zakaria
Mohamed Wafaa Zakaria
AEArmin Ernst
Armin Ernst
The stepwise progression of carcinogenesis is believed to be a potential target for improving the survival of patients with nonsmall cell lung cancer. Data from other epithelial organs, such as the cervix, colon, and esophagus, have shown that the detection of neoplasm at the intraepithelial stage has resulted in an improved cure rate.1 x 1 Lam, S, Kennedy, T, Unger, M et al. Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest. 1998; 113: 696–702 Crossref | PubMed | Scopus (509) | Google Scholar See all References , 2 x 2 Anderson, GH, Boyes, DA, Benedet, JL et al. Organisation and results of the cervical cytology screening programme in British Columbia, 1955–85. Br Med J (Clin Res Ed). 1988; 296: 975–978 Crossref | PubMed | Scopus (165) | Google Scholar See all References , 3 x 3 Winawer, SJ, Zauber, AG, Ho, MN et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993; 329: 1977–1981 Crossref | PubMed | Scopus (3238) | Google Scholar See all References , 4 x 4 Pech, O, May, A, Gossner, L et al. Curative endoscopic therapy in patients with early esophageal squamous-cell carcinoma or high-grade intraepithelial neoplasia. Endoscopy. 2007; 39: 30–35 Crossref | PubMed | Scopus (127) | Google Scholar See all References , 5 x 5 Wright, TC Jr, Massad, LS, Dunton, CJ, Spitzer, M, Wilkinson, EJ, Solomon, D, and 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007; 197: 340–345 Abstract | Full Text | Full Text PDF | PubMed | Scopus (286) | Google Scholar See all References Epithelial changes, such as high-grade dysplasia and carcinoma in situ (CIS), in the airways are regarded as squamous cell carcinoma presenting at an early stage.6 x 6 Auerbach, O, Stout, AP, Hammond, EC, and Garfinkel, L. Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N Engl J Med. 1961; 265: 253–267 Crossref | PubMed | Scopus (422) | Google Scholar See all References , 7 x 7 Bota, S, Auliac, JB, Paris, C et al. Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy. Am J Respir Crit Care Med. 2001; 164: 1688–1693 Crossref | PubMed | Scopus (163) | Google Scholar See all References , 8 x 8 Lee, P and Sutedja, TG. Lung cancer screening: has there been any progress? Computed tomography and autofluorescence bronchoscopy. Curr Opin Pulm Med. 2007; 13: 243–248 Crossref | PubMed | Scopus (14) | Google Scholar See all References , 9 x 9 Brambilla, E, Travis, WD, Colby, TV, Corrin, B, and Shimosato, Y. The new World Health Organization classification of lung tumours. Eur Respir J. 2001; 18: 1059–1068 Crossref | PubMed | Scopus (729) | Google Scholar See all References These lesions bear the hallmarks of neoplasia, which are angiogenesis and structural changes of the mucosa.10 x 10 Shaipanich, T, McWilliams, A, and Lam, S. Early detection and chemoprevention of lung cancer. Respirology. 2006; 11: 366–372 Crossref | PubMed | Scopus (11) | Google Scholar See all References New bronchoscopic technology has targeted these features of neoplasia to improve the detection of preinvasive lesions. Examples of this new technology include white light videobronchoscopy (WLB), autofluorescence imaging (AFI), and narrow band imaging (NBI).

10 June 2010 in Therapeutic Advances in Respiratory Disease
Verified
Journal Article
Closed access
PDF file
FHFelix Jf. Herth
Felix Jf. Herth
RERalf Eberhard
Ralf Eberhard
DGDaniela Gompelmann
Daniela Gompelmann
DSDirk-Jan Slebos
Dirk-Jan Slebos
AEArmin Ernst
Armin Ernst
Background: Lung volume reduction aims to improve symptoms by reducing hyperinflation. Endoscopic approaches so far have generally been hampered in their efficacy by collateral ventilation (CV). We sought to determine the safety and feasibility of a new endoscopic lung volume reduction approach independent of the effects of CV. Methods: Patients with severe emphysema were eligible. Inclusion and exclusion criteria were modeled after the National Emphysema Treatment Trial (NETT) study. Homogenous and heterogeneous disease was allowed. Treatment consisted of the placement of coils into the parenchyma of the most diseased area with the intent of achieving parenchymal compression. Primary endpoints were safety and feasibility assessments. Secondary endpoints were efficacy outcomes. Results: Eleven patients underwent 21 procedures. Procedures were performed under general anesthesia and lasted 45±15 minutes and per procedure 4.9±0.6 coils were placed. All procedures were well tolerated. The total follow-up time was 7-11 months and in that time 33 adverse events were reported, none of them severe. No pneumothorax occurred. Efficacy seemed better in heterogeneous rather than homogenous disease. Conclusion: Endoscopic lung volume reduction with coils is safe and feasible. Further studies of the efficacy are indicated.

1 October 2010 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
RERalf Eberhardt
Ralf Eberhardt
NKNicolas Kahn
Nicolas Kahn
DGDaniela Gompelmann
Daniela Gompelmann
MSMaren Schumann
Maren Schumann
CHClaus Peter Heussel
Claus Peter Heussel
FHFelix Herth
Felix Herth
Introduction: Although flexible bronchoscopy is the least invasive procedure for sampling, it is limited by its inability to reach lesions in the peripheral segments of the lung. Biopsy success is further compromised if the lesion is less than 30 mm in diameter or cannot be seen on fluoroscopy. We wanted to explore whether a new bronchoscopic navigation system could help access the peripheral lung airways and enable lesion sampling. Methods: The LungPoint system produced a virtual bronchoscopic pathway indicating the bronchus into which the bronchoscope should be advanced. Virtual bronchoscopic images were displayed alongside and registered with actual bronchoscopic video. After performing broncoscopy with a standard bronchoscope for first examination, the thin bronchoscope was advanced to the target bronchus under direct visualization without fluoroscopy. A pilot study included consecutive patients at a tertiary teaching hospital with pulmonary peripheral lesions (<42 mm). Biopsies were taken later. Results: Study subjects included 25 patients (9 women and 16 men, mean age 67 years) with 25 lesions (mean size 28 mm). Using this navigation system, the bronchoscope could be advanced along the planned route in all cases. In 14 of the cases (56%), the bronchoscope could be advanced all the way to the lesion bronchus. The planning time was a median of 5 minutes, and the median examination time was 15 minutes. A definitive diagnosis was possible in 20 cases (80%). One patient experienced a small pneumothorax because of the biopsy that resolved without drainage. No other complications occurred. Conclusions: This navigation system is useful for bronchoscopy for pulmonary peripheral lesions (NCT01067755).

11 January 2011 in Respiration
Verified
Journal Article
Open access
PDF file
FHFelix Herth
Felix Herth
DGDaniela Gompelmann
Daniela Gompelmann
FSF. Stanzel
F. Stanzel
RBR. Bonnet
R. Bonnet
JBJ. Behr
J. Behr
RER. Eberhardt
R. Eberhardt
Background: This report summarizes initial tests of an emphysematous lung synthetic polymer sealant (ELS) designed to reduce lung volume in patients with advanced emphysema. Objectives: The primary study objective was to define a therapeutic strategy to optimize treatment safety and effectiveness. Methods: ELS therapy was administered bronchoscopically to 25 patients with heterogeneous emphysema in an open-label, noncontrolled study at 6 centers in Germany. Treatment was performed initially at 2–4 subsegments. After 12 weeks, patients were eligible for repeat therapy to a total of 6 sites. Safety and efficacy were assessed after 6 months. Responses were evaluated in terms of changes from baseline in lung physiology, functional capacity, and health-related quality of life. Follow-up is available for 21 of 25 patients. Results: Treatment was well tolerated. There were no treatment-related deaths (i.e. within 90 days of treatment), and an acceptable short- and long-term safety profile. Physiological and clinical benefits were observed at 24 weeks. Efficacy responses were better among Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage III patients [n = 14; change in residual volume/total lung capacity (ΔRV/TLC) = –7.4 ± 10.3%; Δ forced expiratory volume in 1 s (ΔFEV1) = +15.9 ± 22.6%; change in forced vital capacity (ΔFVC) = +24.1 ± 22.7%; change in carbon monoxide lung diffusion capacity (ΔDLCO) = +19.3 ± 34.8%; change in 6-min walk test (Δ6MWD) = +28.7 ± 59.6 m; change in Medical Research Council Dyspnea (ΔMRCD) score = –1.0 ± 1.04 units; change in St. George’s Respiratory Questionnaire (ΔSGRQ) score = –9.9 ± 15.3 units] than for GOLD stage IV patients (n = 7; ΔRV/TLC = –0.5 ± 6.4%; ΔFEV1 = +2.3 ± 12.3%; ΔFVC = +2.6 ± 21.1%; ΔDLCO = –2.8 ± 17.2%; Δ6MWD = +28.3 ± 58.4 m; ΔMRCD = 0.3 ± 0.81 units; ΔSGRQ = –6.7 ± 7.0 units). Conclusions: ELS therapy shows promise for treating patients with advanced heterogeneous emphysema. Additional studies to assess responses in a larger cohort with a longer follow-up are warranted.